SEC Form 4 · accession 0001213900-18-010085
ADIAL PHARMACEUTICALS, INC. · ADIL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Tony Goodman
Director
Period of report
Jul 31, 2018
Accepted (ET)
Aug 2, 2018 · 4:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001513525
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 31, 2018 | P$0 | 7,000 | — | A | 8,755 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrant to purchase common stockF1 | $6.25 | Jul 31, 2018 | P | 7,000 | A | Jul 31, 2018 | Jul 31, 2023 | Common Stock | 7,000 | 7,000 | D |
Explanation of responses
- F1On July 31, 2018, the reporting person purchased 7,000 units (the "Units") in the initial public offering (the "IPO") of Adial Pharmaceuticals, Inc. (the "Company") at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant). Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the IPO.